Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.5098
+0.00981.96%
Post-market: 0.51000.0002+0.04%19:59 EDT
Volume:2.67M
Turnover:1.36M
Market Cap:184.29M
PE:-0.81
High:0.5262
Open:0.5001
Low:0.4980
Close:0.5000
Loading ...

Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain

TIPRANKS
·
30 Jan

Lexicon rumor highlighted in Betaville alert

TIPRANKS
·
30 Jan

Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Jan

Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham

TIPRANKS
·
29 Jan

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)

TIPRANKS
·
28 Jan

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

GlobeNewswire
·
21 Jan

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey
·
06 Jan

Lexicon Pharmaceuticals Names Scott Coiante Finance Chief

Dow Jones
·
02 Jan

Lexicon appoints Scott Coiante as CFO

TIPRANKS
·
02 Jan

Lexicon Appoints Scott Coiante as Chief Financial Officer

THOMSON REUTERS
·
02 Jan

Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer

Dow Jones
·
02 Jan

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%

Simply Wall St.
·
30 Dec 2024

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)

TIPRANKS
·
25 Dec 2024

Lexicon Pharmaceuticals Shares Fall 9% After FDA Declines to Approve Its Add-on Diabetes Drug

THOMSON REUTERS
·
23 Dec 2024

Top Premarket Decliners

MT Newswires Live
·
23 Dec 2024

Lexicon Pharma Falls 11.9% Premarket After FDA Declines to Approve Its Add-on Diabetes Drug

THOMSON REUTERS
·
23 Dec 2024

BUZZ-Lexicon Pharma falls after FDA declines to approve its add-on diabetes drug

Reuters
·
23 Dec 2024

Needham Remains a Hold on Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
23 Dec 2024

Stocks to Watch: Rumble, Lexicon Pharmaceuticals

Dow Jones
·
21 Dec 2024

Lexicon Receives Complete Response Letter from FDA for Diabetes, Kidney Disease Treatment

Dow Jones
·
21 Dec 2024